Zacks Reiterates “Outperform” Rating for Pure Bioscience (PURE)
Pure Bioscience (NASDAQ:PURE)‘s stock had its “outperform” rating restated by Zacks in a research note issued to investors on Tuesday. They currently have a $3.00 target price on the stock. Zacks‘s price objective points to a potential upside of 172.73% from the company’s current price.
Zacks’ analyst wrote, “PURE develops and markets SDC-based antimicrobial products that provide non-toxic solutions to numerous global health challenges. SDC is a novel, patented platform technology with superior efficacy and low toxicity and can be used in diverse markets including food safety, personal care, preservatives, industrials, agriculture and pharmaceuticals. After recent massive management change, PURE is refocusing on the food safety industry. We expect growth will accelerate in calendar 2H14. We maintain Outperform rating for PURE shares. “
Shares of Pure Bioscience (NASDAQ:PURE) remained flat at $1.10 during trading on Tuesday. The stock had a trading volume of 73,655 shares. Pure Bioscience has a 1-year low of $0.30 and a 1-year high of $1.70. The stock has a 50-day moving average of $1.13 and a 200-day moving average of $1.23. The company’s market cap is $29.9 million.
Pure Bioscience (NASDAQ:PURE) last posted its quarterly earnings results on Tuesday, June 10th. The company reported ($0.07) earnings per share for the quarter. The company had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.26 million.
PURE Bioscience is engaged in the development and commercialization of bioscience technologies. The Company’s flagship bioscience technology is a aqueous antimicrobial called silver dihydrogen citrate (NASDAQ:PURE).
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.